Skip Navigation


  • Our Mission

    To actively accelerate innovations to benefit patients, society, and the Dana-Farber Cancer Institute. We team with investigators to identify new discoveries and generate alliances to move science from bench to clinic for maximum impact.

    Our Vision

    To spark and fuel a spirit of innovation across the organization by providing effective tools to continuously question, create, and imagine what else might be possible.

    Collaboration Opportunities

    In collaborating with Dana-Farber, your organization will have access to the Institute's specialized expertise, and to the unique array of core facilities needed to explore new areas of research. Learn more about Dana-Farber Centers that are interested in partnering with industry. Explore Dana-Farber's extensive Core Facilities. And discover more opportunities to collaborate.

  • BODFI statistics for 2020
  • In partnership with the Innovation Office, Dana-Farber makes publicly available a list of FDA-approved therapeutics and diagnostics in which the Institute has a financial interest.
    View the list

  • Technology News

    Caron Jacobson

    Dana-Farber to Offer First CAR T-cell Therapy for Indolent Follicular Lymphoma Following FDA Approval

    The U.S. Food and Drug Administration (FDA) has approved the CAR T-cell treatment axicabtagene ciloleucel (axi-cel or Yescarta) for patients with indolent follicular lymphoma, a slow growing, non-Hodgkin lymphoma (NHL). Axi-cel was approved as a standard treatment for patients with follicular lymphoma (FL) who have relapsed from, or become resistant to, other treatments. The approval of axi-cel is based on the results of the ZUMA-5 trial, a phase 2 study led by Caron Jacobson, MD, MMSc, and Dana-Farber investigators. Several CAR T-cell therapies, including axi-cel, have received FDA approval for the treatment of aggressive lymphomas, but axi-cel is the first to be approved for indolent forms of the disease ... 


    MMB-FOXM1-Driven Premature Mitosis is Required for CHK1 Inhibitor Sensitivity (Cell)

    Due to oncogene-driven acceleration of cell division, cancer cells may become hyper-dependent on the ATR-CHK1 pathway to manage replication stress and maintain sufficient genomic integrity for continued survival. Inhibitors of ATR and CHK1 have been developed as anti-cancer agents to exploit this vulnerability ... To identify genes whose monogenic loss confers resistance to the CHK1 inhibitor prexasertib, Timothy Branigan, PhD, and James DeCaprio, MD, led genome-wide CRISPR-Cas9 KO screenings in two non-small-cell lung cancer (NSCLC) cell lines (549 and NCI-H460) in the presence of cytotoxic concentrations of prexasertib ... 

    Catherine_Wu_PF_ITI_NON catherine wu SOG_0550_12

    Hotspot Mutation in Transcription Factor IKZF3 Drives B Cell Neoplasia via Transcriptional Dysregulation (Cancer Cell)

    Hotspot mutation of IKZF3 (IKZF3-L162R) has been identified as a putative driver of chronic lymphocytic leukemia (CLL), but its function remains unknown. In a recent study in Cancer Cell, Gregory Lazarian, PhD, and Catherine Wu, MD, investigated its driving role in CLL using a B cell-restricted conditional knockin mouse model. Mutant Ikzf3 alters its normal DNA binding specificity and target selection, leading to hyperactivation of B cell receptor (BCR) signaling, overexpression of nuclear factor κB (NF-κB) target genes, and development of CLL-like disease in elderly mice with a penetrance of ~40% ... 

    Coming Soon: Our Quarterly Newsletter

    Stay current with Dana-Farber technology news, transactions, patents, publications, events, and more.